The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | A.R.R.O.W. study: carfilzomib dosing in frail MM patients
Maria Victoria-Mateos
• 14 Sep 2019
Maria-Victoria Mateos, MD, PhD from the University of Salamanca, Salamanca, Spain, gives an update on the Phase III A.R.R.O.W. study (NCT02412878) looking at carfilzomib dosing in frail MM patients. Dr Mateos was speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.
